Safety and efficacy of catheter directed thrombolysis in children with deep venous thrombosis

Aichberger, K.J., Mayerhofer, M., Krauth, M.T., Vales, A., Kondo, R., Derdak, S., Pickl, W.F., Selzer, E., Deininger, M., Druker, B.J., Sillaber, C., Esterbauer, H. & Valent, P. (2005) Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Research, 65, 9436–9444. Aichberger, K.J., Jagani, Z., Song, K., Kutok, M.R., Melet, A., Santos, T., Grassian, A., Ghaffari, S., Wu, C., Ren, R., Yeckes Rodin, H., Miller, K. & Khosravi-Far, R. (2009) Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Research, 69, 6546–6555. Boultwood, J. & Wainscoat, J.S. (2007) Gene silencing by DNA methylation in haematological malignancies. British Journal of Haematology, 138, 3–11. Jelinek, J., Gharibyan, V., Estecio, M.R.H., Kondo, K., He, R., Chung, W., Lu, Y., Zhang, N., Liang, S., Kantarjian, H.M., Cortes, J.E. & Issa, J.P.J. (2011) Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortnened survival in chronic myelogenous leukemia. PLoS ONE, 6, e22110. Kuribara, R., Honda, H., Matsui, H., Shinjyo, T., Inukai, T., Sugita, K., Nakazawa, S., Hirai, H., Ozawa, K. & Inaba, T. (2004) Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Molecular and Cellular Biology, 24, 6172–6183. Kuroda, J., Puthalakath, H., Cragg, M.S., Kelly, P. N., Bouillet, P., Huang, D.C.S., Kimura, S., Ottmann, O.G., Druker, B.J., Villunger, A., Roberts, A.W. & Strasser, A. (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proceedings National Academy Science USA, 103, 14907–14912. Mancini, M., Veljkovic, N., Leo, E., Aluigi, M., Borsi, E., Galloni, C., Iacobucci, I., Barbieri, E. & Santucci, M.A. (2012) Cytoplasmatic compartimentalization by Bcr-Abl promotes TET2 lossof-function in chronic myeloid leukemia. Journal of Cellular Biochemistry, 113, 2765–2774. Ng, K.P., Hillmer, A.M., Chuah, C.T., Juan, W.C., Ko, T.K., Teo, A.S., Ariyaratne, P.N., Takahashi, N., Sawada, K., Fei, Y., Soh, S., Lee, W.H., Huang, J.W., Allen, Jr, J.C., Woo, X.Y., Nagarajan, N., Kumar, V., Thalamuthu, A., Poh, W.T., Ang, A.L., Mya, H.T., How, G.F., Yang, L.Y., Koh, L.P., Chowbay, B., Chang, C.T., Nadarajan, V.S., Chng, W.J., Than, H., Lim, L.C., Goh, Y.T., Zhang, S., Poh, D., Tan, P., Seet, J.E., Ang, M.K., Chau, N. M., Ng, Q.S., Tan, D.S., Soda, M., Isobe, K., Nöthen, M.M., Wong, T.Y., Shahab, A., Ruan, X., Cacheux-Rataboul, V., Sung, W.K., Tan, E.H., Yatabe, Y., Mano, H., Soo, R.A., Chin, T.M., Lim, W.T., Ruan, Y. & Ong, S.T. (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior response to tyrosine kinase inhibitors in cancer. Nature Medicine, 18, 521– 528. San José-Eneriz, E., Agirre, X., Jiménez-Velasco, A., Cordeu, L., Martin, V., Arqueros, V., Garate, L., Fresquet, V., Cervantes, F., Martinez-Climent, J.A., Heiniger, A., Torres, A., Prosper, F. & Roman-Gomez, J. (2009) Epigenetic downregulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukemia. European Journal of Cancer, 45, 1877–1889. Youle, R.J. & Strasser, S. (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews. Molecular Cell Biology, 9, 47–59.